OptimizeRx Corporation — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The unaudited consolidated results include the October 2023 acquisition of Medicx Health. Amounts below are in U.S. dollars; financial statement amounts are shown in millions unless noted.
Business context and performance
OptimizeRx provides digital health technology and marketing services connecting life sciences organizations, healthcare providers, and patients through point-of-care and other digital channels. Its offerings include DAAP, which management describes as an AI-enabled audience and channel optimization platform.
- Revenue was $19.69 million, up 51% from $13.00 million. The increase reflected Medicx Health and growth in DAAP-related sales, partly offset by the exit from non-core Access and other solutions.
- For a more comparable view, management adjusted the prior-year figures for the acquired business and the exited non-core revenue: 2024 revenue of $19.69 million versus adjusted 2023 revenue of $19.16 million, an increase of about 3%.
- Gross profit was $12.20 million versus $7.43 million; gross margin improved to 62.0% from 57.2%. Management attributed the improvement to solution and channel mix, including higher-margin DAAP revenue and more cost-effective channel partners.
- Operating expenses were $17.23 million, up 19%. General and administrative expense increased, including from acquired-business headcount, professional fees, and partner integration incentives; stock-based compensation declined.
- Operating loss was $5.03 million, compared with $7.06 million. Net loss widened to $6.90 million from $6.40 million, and diluted loss per share was $0.38 versus $0.37. Results included $1.55 million of interest expense, while interest income fell to $0.02 million from $0.67 million.
Cash, liquidity, and debt
- Operating cash flow was positive $2.12 million, versus cash used of $0.09 million a year earlier. Management cited receivable collections and $4.27 million of non-cash expenses as important factors.
- Investing cash outflow was $0.15 million, mainly software development and equipment. Financing cash outflow was $0.64 million, including a $0.50 million term-loan repayment and $0.14 million of employee tax withholding payments.
- Cash and cash equivalents were $15.18 million at quarter-end, up from $13.85 million at year-end. Working capital was $31.6 million, with a current ratio of 2.9, compared with $36.4 million and 3.0 at December 31, 2023.
- Term-loan principal was $37.79 million; the balance-sheet carrying amount, net of issuance costs, was $32.41 million. The loan bore interest at 14.1% (16.0% effective rate), is due in 2027, and requires scheduled repayments and potentially annual excess-cash-flow prepayments beginning in 2025. The company reported compliance with financial covenants.
- Management said existing cash and anticipated operating cash generation should fund operations and debt obligations for the next 12 months, while noting it may seek additional financing for acquisitions, strategic relationships, capital expenditures, or working capital.
Other material developments, outlook, and risks
- Medicx Health contributed to reported growth but complicates year-over-year comparisons. The company also disposed of non-core Access solutions and certain related contracts in Q4 2023.
- Management reported rolling 12-month net revenue retention of 116%, versus 86% a year earlier, and average revenue per top-20 pharmaceutical manufacturer of $2.537 million, versus $1.823 million. Management attributed improvement in part to DAAP and Medicx Health.
- No specific quarterly or annual revenue or earnings guidance is provided in the supplied filing text. Management notes that pharmaceutical marketing is generally seasonal, with Q1 tending to have lower activity and revenue than later quarters.
- The company disclosed approximately $22.6 million of future minimum partner payments for media, data, or messaging capabilities, expected to be reflected in cost of revenues through 2028. The filing’s commitments note labels the measurement date as March 31, 2023, while MD&A says March 31, 2024; confirm the intended date and schedule.
- Disclosure controls and procedures were deemed ineffective at the reasonable-assurance level because of a previously reported material weakness in internal control over financial reporting involving third-party service organizations. Remediation efforts include obtaining SOC 1 Type 2 reports or conducting alternative testing and controls.
- Key stated risks include customer concentration, dependence on healthcare and e-prescribing platform partners, ability to integrate acquisitions and realize benefits, servicing debt and generating cash, healthcare regulation, cybersecurity, macroeconomic conditions, and remediation of the material weakness. No material legal proceedings were reported.
- A $15 million share-repurchase authorization expired March 12, 2024; no shares were repurchased in Q1.
Important facts for investors to verify
- Whether the approximately $22.6 million partner-commitment disclosure is measured as of March 31, 2024, and the applicable payment schedule.
- How much reported growth reflects Medicx Health and DAAP versus underlying comparable organic growth, and whether margin gains persist.
- Receivables collectability and cash conversion, given $29.75 million of accounts receivable and the quarter’s reliance on collections to generate operating cash.
- Debt terms, the effect of the 14.1% stated rate and scheduled repayments, and any excess-cash-flow prepayment obligations.
- Progress in remediating the material weakness and the timing of any conclusion that controls are effective.
- Customer concentration and the sustainability of the reported retention and top-pharmaceutical-customer metrics.